Market Eyes LiveMetLife, Inc. (MET) Stock Rating & Analysis
MELANY's data-driven read on MetLife, Inc. · Life Insurance.
MetLife is one of the largest US life insurers by assets, offering a range of life insurance and annuity products. It operates through six segments - Group Benefits, Retirement and Income Solutions, Asia, Latin America, EMEA, and MetLife Holdings (run-off products) - with the US-based Group Benefits and RIS contributing about 48% of 2024 adjusted earnings and the Asia segment about 25%, mostly tied to Japan.
Why MET scores 66/100
MELANY scores MetLife, Inc. 66/100 by weighing eight factors. Here is how MET breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 8.6x, earnings growth accelerating
- PEG ratio 0.53 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +5%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for MET
- Negative free cash flow, company consuming cash, not generating it
Sector and theme context
MetLife, Inc. sits in the Financials / rate cycle theme, which MELANY currently rates 56/100 for strength. Theme strength feeds MET's momentum and catalyst factors above.
MET trade plan (members only)
MELANY has a full position plan for MetLife, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates MET
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. MetLife, Inc.'s 66/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MET
Is MetLife, Inc. (MET) a buy?
As of 2026-08-20, MELANY rated MetLife, Inc. Favorable with a composite score of 66/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is MetLife, Inc.'s MELANY score?
MetLife, Inc. (MET) has a MELANY composite score of 66/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the MET stock rating calculated?
MELANY scores MET from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy MetLife, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates MetLife, Inc. (MET) Favorable with a composite of 66/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MET stock price forecast?
MELANY does not publish price targets or forecasts for MET. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 66/100 across eight factors for MetLife, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is MET stock overvalued or undervalued?
MELANY's valuation factor currently reads 57/100 for MetLife, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MET's read.
What price should I buy MET at?
Rather than chasing the current price, MELANY computes a smart entry zone for MET: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying MET stock?
The top risks MELANY currently flags for MetLife, Inc.: Negative free cash flow, company consuming cash, not generating it. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is MetLife, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 32/100 for MetLife, Inc., and earnings track record, at 80/100. The 66/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MET stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 70/100 for MET right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MET rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores MET continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
MET's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.